Destiny Pharma PLC Destiny Pharma notes UK 5-year action plan on AMR
January 24 2019 - 5:50AM
RNS Non-Regulatory
TIDMDEST
Destiny Pharma PLC
24 January 2019
Destiny Pharma plc
("Destiny Pharma" or "the Company")
Destiny Pharma notes release of UK Government's Vision and
5-year action plan to help tackle anti-microbial resistance (AMR),
which includes additional investment in innovation
Government's plan consistent with Destiny Pharma's objective of
developing novel anti-infectives from its proprietary XF
platform.
Brighton, United Kingdom - 24 January 2019 - Destiny Pharma
(AIM: DEST), a clinical stage biotechnology company focused on the
development of novel antimicrobial drugs, which address the global
problem of anti-microbial resistance (AMR), notes the publication
of the UK Government's 20-year vision and 5-year action plan on AMR
which outlines how the government will contribute to the global
effort against AMR through optimising use of antimicrobials and
investing in innovation, supply and access.
Neil Clark, Chief Executive Officer of Destiny Pharma
commented:
"Destiny Pharma welcomes the UK government's announcements today
that highlight the UK and global concern about the continuing
threat to human health from AMR and the lack of new, innovative
approaches to preventing and treating bacterial infections. Destiny
Pharma also welcomes government recognition of the need for
financial support for companies carrying out research and drug
development for anti-infectives that address AMR and new financial
incentives for pharmaceutical companies that distribute and sell
anti-infective drugs."
Destiny Pharma's strategy is set out to meet the challenge
outlined in the UK's 5-year action plan, with its XF platform being
developed to deliver novel anti-infective drugs that specifically
address the global challenge of AMR. Its lead programme, XF-73, is
in clinical studies for the prevention of costly, post-surgical
infections such as Methicillin-resistant Staphylococcus aureus
(MRSA). Unlike most antibiotics, XF-73 has not been seen to
generate bacterial resistance in industry-standard microbiology
tests to date and therefore also has significant potential to
address the global threat of AMR alongside its fast, safe and
effective anti-infective action.
Find out more about the UK's plans to see AMR contained and
controlled by 2040 via the two links below:
-- UK 20-year vision for antimicrobial resistance
-- UK 5-year action plan for antimicrobial resistance 2019 to 2024
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
pressoffice@destinypharma.com
+44 (0)1273 704 440
FTI Consulting
Simon Conway / Victoria Foster Mitchell
destinypharma@fticonsulting.com
+44 (0) 20 3727 1000
Cantor Fitzgerald Europe (Nominated Adviser and Joint
Broker)
Philip Davies / Will Goode, Corporate Finance
Andrew Keith, Healthcare Equity Sales
+44 (0)20 7894 7000
finnCap Ltd (Joint Broker)
Geoff Nash /Kate Bannatyne, Corporate Finance
Alice Lane ECM
+44 (0)20 7220 0500
About XF-73
XF-73 is a synthetic anti-microbial active against all tested
Staphylococcus aureus strains, including drug resistant strains. By
acting via a cell-surface mechanism it affects the bacterial
membrane permeability and integrity, leading to cell death. XF-73
has already been through five successful Phase I/IIb clinical
trials showing rapid antibacterial action. In standard microbiology
studies XF drugs have demonstrated a unique no/low resistance
profile that means that XF compounds have the potential to deliver
novel drugs that are clearly differentiated from traditional
antibiotics where resistance limits their utility.
XF-73 is being studies for the prevention of post-surgical
staphylococcal infections. In the US, there are approximately 40
million surgeries per annum alone where the patient is at risk of a
post-surgical infection. However, within this large population
there are particular groups who are at an even higher risk of
infection due to the nature of their surgery or the procedures
and/or their specific hospital environment in which they are
treated. These higher risk surgical procedures include
cardiovascular, orthopaedic and other complex surgeries. Destiny
Pharma estimates that this totals approximately 14 million US
surgeries per year, with this figure set to rise within the context
of an ageing population.
About Destiny Pharma
Destiny Pharma is an established, clinical stage, innovative
biotechnology company focused on the development of novel medicines
that represent a new approach to the treatment of infectious
disease. These potential new medicines are being developed to
address the need for new drugs for the prevention and treatment of
life-threatening infections caused by antibiotic-resistant
bacteria, often referred to as "superbugs". Tackling anti-microbial
resistance has become a global imperative recognised by the WHO and
the United Nations, as well as the G7 and the G20 countries. For
further information, please visit https://www.destinypharma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRADMGZMMDRGLZM
(END) Dow Jones Newswires
January 24, 2019 06:50 ET (11:50 GMT)
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From Apr 2024 to May 2024
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From May 2023 to May 2024